Imagine trying to find the right key for a lock, but you have to try hundreds of keys one by one over several days. This tool is like a high-speed scanner that tests dozens of 'biological keys' (phages) against a bacteria infection almost instantly. It tells doctors exactly which treatment will work in a few hours instead of a week, saving critical time for the patient.
Current phage susceptibility tests are too slow (up to 7 days) and labor-intensive for hospital use. This delay makes personalized phage therapy impractical for treating urgent antimicrobial-resistant infections.
An automated IVD tool called 'Phagogram' comprising a disposable well plate kit, a high-performance luminometer, and matching software.
If you are a hospital lab dealing with slow, labor-intensive susceptibility testing that takes 4-7 days — this project developed the Phagogram that identifies active phages within 2-3 hours. This allows for routine personalized therapy in a clinical setting.
If you are a biotech company dealing with low efficacy (20-30%) of generic phage cocktails — this project developed a diagnostic tool that enables a personalized approach with a success rate of over 85%. It matches your phage APIs to the specific patient infection.
If you are a manufacturer dealing with the need for automated AMR diagnostics — this project developed a system consisting of a disposable well plate, a luminometer, and software. It scales the testing capacity up to 96 phages per culture.
Based on available project data, the specific pricing or cost of the kit and luminometer is not disclosed.
Yes, the project focused on industrial production development of the prototype, following European Regulations for In Vitro Diagnostic tests.
Based on available project data, the tool was developed by Inteliphage/Vésale Bioscience, but specific licensing terms are not provided.
It replaces slow manual techniques with an automated kit and software that reduces testing time from 4-7 days down to 2-3 hours.
The project period runs from 2023-02-01 to 2025-10-31, indicating it is currently in the development and testing phase.
The project is led by a single Belgian SME, Inteliphage, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as there are no academic or research partners involved, meaning the project is geared toward a direct product launch rather than basic research.
Contact Inteliphage in Belgium for partnership or licensing inquiries.
Contact SciTransfer for a detailed market analysis of the phage diagnostic landscape.
